Pipeline — registered trials by phase
Open-Label Study With Pimavanserin on Activities of Daily Living in Subjects With Parkinson's Disease Psychosis
— · Parkinson Disease Psychosis · Completed · est. 2022-04-26
No registered trials in this stage.
An Open-label Safety Study of Pimavanserin in Parkinson's Disease Patients
— · Parkinson's Disease Psychosis · Completed · est. 2013-05-02
ACP-104 in Acutely Psychotic Subjects With Schizophrenia
— · Schizophrenia · Completed · est. 2008-02
Treatment of Hallucinosis/Psychosis in Parkinson's Disease by an Investigational Drug
— · Hallucinations, Psychoses, Parkinson's Disease · Completed
Safety and Efficacy of Pimavanserin in Adults With Parkinson's Disease and Depression
— · Treatment of Depression in Adults With Parkinson's Disease (PD) · Completed · est. 2019-07-09
Evaluate the Efficacy and Safety of ACP-044 for the Treatment of Acute Postoperative Pain Following Bunionectomy
— · Acute Postoperative Pain, Bunionectomy · Completed · est. 2022-02-11
A Study of Pimavanserin for the Treatment of Agitation and Aggression in Subjects With Alzheimer's Disease
— · Agitation and Aggression in Alzheimer's Disease · Completed · est. 2019-02-25
Antipsychotic and Motor Effects of ACP-103 When Administered in Combination With Haloperidol and Risperidone
— · Schizophrenia · Completed
Phase 2, Efficacy and Safety Study of ACP-204 in Lewy Body Dementia Psychosis
— · Lewy Body Dementia Psychosis · Recruiting · est. 2028-02
A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis
— · Alzheimer's Disease Psychosis · Completed · est. 2016-09-28
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
— · Major Depressive Disorder (MDD), Depressive Disorder, Treatment-Resistant · Recruiting · est. 2027-08
Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin in Major Depressive Disorder (CLARITY)
— · Adjunctive Treatment of Major Depressive Disorder · Completed · est. 2018-09
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE)
— · Schizophrenia · Completed · est. 2019-10-16
Pimavanserin for the Treatment of Irritability Associated With Autism Spectrum Disorder
— · Irritability Associated With Autism Spectrum Disorder · Completed · est. 2024-09-27
A Study of the Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
— · Parkinson's Disease Psychosis · Completed · est. 2009-06
Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)
— · Schizophrenia · Completed · est. 2019-05-28
Phase 3, Open Label Extension Study of ACP-204 in Lewy Body Dementia Psychosis
— · Lewy Body Dementia Psychosis · Recruiting · est. 2029-02
Open-Label Extension Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome
— · Rett Syndrome · Completed · est. 2022-08-19
Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
— · Dementia-related Psychosis · Completed · est. 2019-07-31
A Study of the Safety and Tolerability of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
— · Parkinson's Disease Psychosis · Completed · est. 2018-05-30
A Study of the Safety and Efficacy of Pimavanserin in Patients With Parkinson's Disease Psychosis
— · Parkinson's Disease Psychosis · Completed · est. 2012-11
Extension Study of Pimavanserin in Adult Subjects With Neuropsychiatric Symptoms Related to Neurodegenerative Disease
— · Neuropsychiatric Symptoms Related to Neurodegenerative Disease · Completed · est. 2023-05-05
Study of Trofinetide for the Treatment of Girls and Women With Rett Syndrome (LAVENDER™)
— · Rett Syndrome · Completed · est. 2021-10-28
ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study
— · Alzheimer's Disease Psychosis · Enrolling By Invitation · est. 2029-04
A Safety Study of Pimavanserin in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease
— · Neuropsychiatric Symptoms Related to Neurodegenerative Disease · Completed · est. 2022-05-06
Efficacy and Safety of Pimavanserin as Adjunctive Treatment for the Negative Symptoms of Schizophrenia
— · Schizophrenia · Completed · est. 2024-01-25
Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment
— · Adjunctive Treatment of Major Depressive Disorder · Completed · est. 2020-04-30
Study of Carbetocin Nasal Spray for the Treatment of Hyperphagia in Prader-Willi Syndrome
— · Hyperphagia in Prader-Willi Syndrome · Active Not Recruiting · est. 2025-10
A Study of Safety and Efficacy of Pimavanserin (ACP-103) in Patients With Parkinson's Disease Psychosis
— · Parkinson's Disease Psychosis · Completed · est. 2009-12
ACP-204 in Adults With Alzheimer's Disease Psychosis
— · Alzheimer's Disease Psychosis · Recruiting · est. 2028-01
No approved products listed under this sponsor in Drugs@FDA (partnered or subsidiary products may be listed elsewhere).
Source: ClinicalTrials.gov (trials where Acadia is lead sponsor; 30 active or completed) and Drugs@FDA (0 approved products). Registry data can include older or partnered programs; the company's own pipeline page is the official list.
SEC filings — insider trading forms excluded
- 8-K2026-09-24Current report (material event)
- 8-K2026-09-11Current report (material event)
- SCHEDULE 13G2026-08-07SCHEDULE 13G
- 10-Q2026-08-05Quarterly report
- 8-K2026-08-04Current report (material event)
- S-82026-06-10Employee stock plan
- 8-K2026-05-29Current report (material event)
- 10-Q2026-05-07Quarterly report
- 8-K2026-05-06Current report (material event)
- 8-K2026-05-01Current report (material event)
- SCHEDULE 13G2026-04-28SCHEDULE 13G
- ARS2026-04-24Annual report to holders
- DEF 14A2026-04-24Proxy statement
- SCHEDULE 13G/A2026-03-26SCHEDULE 13G/A
- 8-K2026-03-05Current report (material event)
- SCHEDULE 13D/A2026-02-26SCHEDULE 13D/A
- 10-K2026-02-26Annual report
- 8-K2026-02-25Current report (material event)
- 8-K2026-01-13Current report (material event)
- SCHEDULE 13G/A2025-11-14SCHEDULE 13G/A
- 10-Q2025-11-06Quarterly report
- 8-K2025-11-05Current report (material event)
- 8-K2025-11-03Current report (material event)
- 10-Q2025-08-07Quarterly report
- 8-K2025-08-06Current report (material event)
- 8-K2025-06-10Current report (material event)
- 8-K2025-05-29Current report (material event)
- EFFECT2025-05-23EFFECT
- CORRESP2025-05-21CORRESP
- 8-K2025-05-20Current report (material event)
- UPLOAD2025-05-14UPLOAD
- S-32025-05-09Shelf registration
- 10-Q2025-05-08Quarterly report
- 8-K2025-05-07Current report (material event)
- ARS2025-04-25Annual report to holders
- DEF 14A2025-04-25Proxy statement
- 8-K2025-04-16Current report (material event)
- 10-K2025-02-27Annual report
- 8-K2025-02-26Current report (material event)
- SCHEDULE 13G/A2025-02-14SCHEDULE 13G/A
Source: SEC EDGAR. Forms 3/4/5 and 144 (insider transactions) are intentionally left out.